Who are isoniazid , randomized, open label's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Preventive treatment with Isoniazid, Isoniazid (Rifinah), Isoniazid (INH), INH preventive therapy, Isoniazid (H), Isoniazid with Ethambutol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isoniazid-randomized-open-label.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

isoniazid , randomized, open label — Competitive Intelligence Brief

isoniazid , randomized, open label (isoniazid , randomized, open label) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antitubercular agent. Area: Infectious disease.

phase 3 Antitubercular agent InhA Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

isoniazid , randomized, open label (isoniazid , randomized, open label) — National Taiwan University Hospital. Isoniazid inhibits the synthesis of mycolic acid in Mycobacterium tuberculosis by inhibiting the enzyme enoyl-acyl carrier protein reductase (InhA).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
isoniazid , randomized, open label TARGET	isoniazid , randomized, open label	National Taiwan University Hospital	phase 3	Antitubercular agent	InhA
Preventive treatment with Isoniazid	Preventive treatment with Isoniazid	Hospital Universitari de Bellvitge	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase); KatG (catalase-peroxidase)
Isoniazid (Rifinah)	Isoniazid (Rifinah)	National Taiwan University Hospital	marketed	Antituberculous agent	Enoyl-ACP reductase (InhA)
Isoniazid (INH)	Isoniazid (INH)	National Institutes of Health Clinical Center (CC)	marketed	Antituberculous agent	InhA (enoyl-ACP reductase)
INH preventive therapy	INH preventive therapy	Johns Hopkins University	marketed	Antimycobacterial agent	InhA (enoyl-ACP reductase)
Isoniazid (H)	Isoniazid (H)	University College, London	phase 3	Nicotinamide analog; first-line antituberculous agent	Enoyl-ACP reductase (InhA); catalase-peroxidase (KatG)
Isoniazid with Ethambutol	Isoniazid with Ethambutol	Tuberculosis Research Centre, India	phase 3	Antituberculous agents	InhA (isoniazid); arabinosyl transferases (ethambutol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antitubercular agent class)

National Taiwan University Hospital · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). isoniazid , randomized, open label — Competitive Intelligence Brief. https://druglandscape.com/ci/isoniazid-randomized-open-label. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab